Status and phase
Conditions
Treatments
About
The objectives of this study are to evaluate the safety and efficacy of certolizumab pegol as add-on medication to methotrexate over the long term in Japanese RA patients transferred from Study 275-08-001 (NCT00791999), and to evaluate the effects of different dosing regimens on the safety and efficacy of certolizumab pegol in American College of Rheumatology 20% (ACR20) responders who completed Study 275-08-001.
Full description
This study was initiated by Otsuka Pharmaceutical Co., Ltd and transferred to Astellas on 12/04/2012.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Subjects who participated in Study 275-08-001 and meet all of the criteria described below.
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
285 participants in 2 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal